{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:52:13Z","timestamp":1740135133434,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T00:00:00Z","timestamp":1711584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 2347\/11-1"],"award-info":[{"award-number":["RA 2347\/11-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Group sequential designs incorporating the option to stop for futility at the time point of an interim analysis can save time and resources. Thereby, the choice of the futility boundary importantly impacts the design\u2019s resulting performance characteristics, including the power and probability to correctly or wrongly stop for futility. Several authors contributed to the topic of selecting good futility boundaries. For binary endpoints, Simon\u2019s designs (Control Clin Trials 10:1\u201310, 1989) are commonly used two-stage designs for single-arm phase II studies incorporating futility stopping. However, Simon\u2019s optimal design frequently yields an undesirably high probability of falsely declaring futility after the first stage, and in Simon\u2019s minimax design often a high proportion of the planned sample size is already evaluated at the interim analysis leaving only limited benefit in case of an early stop.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This work focuses on the optimality criteria introduced by Sch\u00fcler et al. (BMC Med Res Methodol 17:119, 2017) and extends their approach to binary endpoints in single-arm phase II studies. An algorithm for deriving optimized futility boundaries is introduced, and the performance of study designs implementing this concept of optimal futility boundaries is compared to the common Simon\u2019s minimax and optimal designs, as well as modified versions of these designs by Kim et al. (Oncotarget 10:4255\u201361, 2019).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The introduced optimized futility boundaries aim to maximize the probability of correctly stopping for futility in case of small or opposite effects while also setting constraints on the time point of the interim analysis, the power loss, and the probability of stopping the study wrongly, i.e. stopping the study even though the treatment effect shows promise. Overall, the operating characteristics, such as maximum sample size and expected sample size, are comparable to those of the classical and modified Simon\u2019s designs and sometimes better. Unlike Simon\u2019s designs, which have binding stopping rules, the optimized futility boundaries proposed here are not adjusted to exhaust the full targeted nominal significance level and are thus still valid for non-binding applications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The choice of the futility boundary and the time point of the interim analysis have a major impact on the properties of the study design. Therefore, they should be thoroughly investigated at the planning stage. The introduced method of selecting optimal futility boundaries provides a more flexible alternative to Simon\u2019s designs with non-binding stopping rules. The probability of wrongly stopping for futility is minimized and the optimized futility boundaries don\u2019t exhibit the unfavorable properties of an undesirably high probability of falsely declaring futility or a high proportion of the planned sample evaluated at the interim time point.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12874-024-02190-w","type":"journal-article","created":{"date-parts":[[2024,3,28]],"date-time":"2024-03-28T05:43:00Z","timestamp":1711604580000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimal futility stopping boundaries for binary endpoints"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0924-1277","authenticated-orcid":false,"given":"Michaela\u00a0Maria","family":"Freitag","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1443-4032","authenticated-orcid":false,"given":"Xieran","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2451-1660","authenticated-orcid":false,"given":"Geraldine","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"4","key":"2190_CR1","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1177\/009286150103500408","volume":"35","author":"S Pampallona","year":"2001","unstructured":"Pampallona S, Tsiatis AA, Kim K. Interim Monitoring of Group Sequential Trials Using Spending Functions for the Type I and Type II Error Probabilities. Drug Inf J. 2001;35(4):1113\u201321. https:\/\/doi.org\/10.1177\/009286150103500408.","journal-title":"Drug Inf J."},{"key":"2190_CR2","doi-asserted-by":"publisher","unstructured":"He P, Leung T, Liao O. Futility stopping in clinical trials. Stat Interf. 2012;5. https:\/\/doi.org\/10.4310\/SII.2012.v5.n4.a4.","DOI":"10.4310\/SII.2012.v5.n4.a4"},{"key":"2190_CR3","doi-asserted-by":"publisher","unstructured":"Gallo P, Mao L, Shih V. Alternative Views On Setting Clinical Trial Futility Criteria. J Biopharm Stat. 2014;24. https:\/\/doi.org\/10.1080\/10543406.2014.932285.","DOI":"10.1080\/10543406.2014.932285"},{"key":"2190_CR4","doi-asserted-by":"publisher","unstructured":"Pilz M, Kunzmann K, Herrmann C, Rauch G, Kieser M. A variational approach to optimal two-stage designs. Stat Med. 2019;38. https:\/\/doi.org\/10.1002\/sim.8291.","DOI":"10.1002\/sim.8291"},{"key":"2190_CR5","doi-asserted-by":"publisher","first-page":"096228021774731","DOI":"10.1177\/0962280217747312","volume":"28","author":"T Ondra","year":"2017","unstructured":"Ondra T, Jobj\u00f6rnsson S, Beckman R, Burman CF, K\u00f6nig F, Stallard N, et al. Optimized adaptive enrichment designs. Stat Methods Med Res. 2017;28:096228021774731. https:\/\/doi.org\/10.1177\/0962280217747312.","journal-title":"Stat Methods Med Res."},{"key":"2190_CR6","doi-asserted-by":"publisher","unstructured":"Xi D, Gallo P, Ohlssen D. On the Optimal Timing of Futility Interim Analyses. Stat Biopharm Res. 2017;9. https:\/\/doi.org\/10.1080\/19466315.2017.1340906.","DOI":"10.1080\/19466315.2017.1340906"},{"key":"2190_CR7","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1002\/sim.2087","volume":"24","author":"AL Gould","year":"2005","unstructured":"Gould AL. Timing of futility analyses for \u2018proof of concept\u2019 trials. Stat Med. 2005;24:1815\u201335. https:\/\/doi.org\/10.1002\/sim.2087.","journal-title":"Stat Med."},{"issue":"4","key":"2190_CR8","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","volume":"13","author":"EA Gehan","year":"1961","unstructured":"Gehan EA. The Determination of the Number of Patients Required in a Preliminary and a Follow-Up Trial of a New Chemotherapeutic Agent. J Chronic Dis. 1961;13(4):346\u201353.","journal-title":"J Chronic Dis."},{"issue":"1","key":"2190_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1\u201310. https:\/\/doi.org\/10.1016\/0197-2456(89)90015-9.","journal-title":"Control Clin Trials."},{"key":"2190_CR10","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/sim.1600","volume":"23","author":"SH Jung","year":"2004","unstructured":"Jung SH, Lee T, Kim K, George S. Admissible two-stage designs for Phase II cancer clinical trials. Stat Med. 2004;23:561\u20139. https:\/\/doi.org\/10.1002\/sim.1600.","journal-title":"Stat Med."},{"key":"2190_CR11","doi-asserted-by":"publisher","first-page":"4255","DOI":"10.18632\/oncotarget.26981","volume":"10","author":"J Kim","year":"2019","unstructured":"Kim J, Schell M. Modified Simon\u2019s minimax and optimal two-stage designs for single-arm phase II cancer clinical trials. Oncotarget. 2019;10:4255\u201361.","journal-title":"Oncotarget."},{"key":"2190_CR12","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1111\/j.1541-0420.2010.01402.x","volume":"66","author":"A Tamhane","year":"2010","unstructured":"Tamhane A, Mehta C, Liu L. Testing a Primary and a Secondary Endpoint in a Group Sequential Design. Biometrics. 2010;66:1174\u201384.","journal-title":"Biometrics."},{"key":"2190_CR13","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1002\/sim.6487","volume":"34","author":"M Kieser","year":"2015","unstructured":"Kieser M, Rauch G. Two-stage designs for cross-over bioequivalence trials. Stat Med. 2015;34:2403\u201316.","journal-title":"Stat Med."},{"key":"2190_CR14","unstructured":"Committee for Proprietary Medicinal Products. Points to consider on multiplicity issues in clinical trials. Technical report, European Medicines Agency. 2002."},{"key":"2190_CR15","doi-asserted-by":"crossref","unstructured":"Sch\u00fcler S, Kieser M, Rauch G. Choice of futility boundaries for group sequential designs with two endpoints. BMC Med Res Methodol. 2017;17:119.\u00a0https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-017-0387-4.","DOI":"10.1186\/s12874-017-0387-4"},{"key":"2190_CR16","doi-asserted-by":"publisher","unstructured":"Li X, Herrmann C, Rauch G. Optimality criteria for futility stopping boundaries for group sequential designs with a continuous endpoint. BMC Med Res Methodol. 2020;20. https:\/\/doi.org\/10.1186\/s12874-020-01141-5.","DOI":"10.1186\/s12874-020-01141-5"},{"issue":"8","key":"2190_CR17","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1002\/sim.3538","volume":"28","author":"F Bretz","year":"2009","unstructured":"Bretz F, Koenig F, Brannath W, Glimm E, Posch M. Adaptive designs for confirmatory clinical trials. Stat Med. 2009;28(8):1181\u2013217.","journal-title":"Stat Med."},{"key":"2190_CR18","unstructured":"Berry Consultants. ADDPLAN: Adaptive Designs - Plans and Analyses. 2024. https:\/\/www.berryconsultants.com\/software\/addplan\/. Accessed 4 March 2024."},{"key":"2190_CR19","doi-asserted-by":"crossref","unstructured":"Assmer G, Pahlke F. Rpact: Confirmatory Adaptive Clinical Trial Design and Analysis. 2018. https:\/\/rdrr.io\/cran\/rpact\/man\/rpact.html. Accessed 4 March 2024.","DOI":"10.32614\/CRAN.package.rpact"},{"key":"2190_CR20","doi-asserted-by":"publisher","unstructured":"Jin H, Wei Z. A new adaptive design based on Simon\u2019s two-stage optimal design for phase II clinical trials. Contemp Clin Trials. 2012;33. https:\/\/doi.org\/10.1016\/j.cct.2012.07.003.","DOI":"10.1016\/j.cct.2012.07.003"},{"key":"2190_CR21","doi-asserted-by":"publisher","unstructured":"Mander AP, Thompson SG. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemp Clin Trials. 2010;31. https:\/\/doi.org\/10.1016\/j.cct.2010.07.008.","DOI":"10.1016\/j.cct.2010.07.008"},{"key":"2190_CR22","doi-asserted-by":"publisher","unstructured":"Parashar D, Bowden J, Starr C, Wernisch L, Mander A. An optimal stratified Simon two-stage design. Pharm Stat. 2016;15. https:\/\/doi.org\/10.1002\/pst.1742.","DOI":"10.1002\/pst.1742"},{"key":"2190_CR23","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2307\/2531294","volume":"41","author":"E Atkinson","year":"1985","unstructured":"Atkinson E, Brown B. Confidence Limits for Probability of Response in Multistage Phase II Clinical Trials. Biometrics. 1985;41:741\u20134. https:\/\/doi.org\/10.2307\/2531294.","journal-title":"Biometrics."},{"key":"2190_CR24","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1002\/sim.3123","volume":"27","author":"T Koyama","year":"2008","unstructured":"Koyama T, Chen H. Proper inference from Simon\u2019s 2-stage designs. Stat Med. 2008;27:3145\u201354. https:\/\/doi.org\/10.1002\/sim.3123.","journal-title":"Stat Med."},{"key":"2190_CR25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12874-015-0039-5","volume":"15","author":"J Zhao","year":"2015","unstructured":"Zhao J, Yu M, Feng XP. Statistical inference for extended or shortened phase II studies based on Simon\u2019s two-stage designs. BMC Med Res Methodol. 2015;15:48. https:\/\/doi.org\/10.1186\/s12874-015-0039-5.","journal-title":"BMC Med Res Methodol."},{"key":"2190_CR26","doi-asserted-by":"crossref","unstructured":"Dimairo M, Pallmann P, Wason J, Todd S, Jaki T, Julious SA, et\u00a0al. The Adaptive designs CONSORT Extension (ACE) statement: a checklist with explanation and elaboration guideline for reporting randomised trials that use an adaptive design. BMJ. 2020;369.\u00a0https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-020-04334-x#citeas.","DOI":"10.1136\/bmj.m115"},{"key":"2190_CR27","doi-asserted-by":"publisher","unstructured":"Lin M, Lee S, Zhen B, Scott J, Horne A, Solomon G, et\u00a0al. CBER\u2019s Experience With Adaptive Design Clinical Trials. Ther Innov Regul Sci. 2015;50. https:\/\/doi.org\/10.1177\/2168479015604181.","DOI":"10.1177\/2168479015604181"},{"key":"2190_CR28","unstructured":"CDER, CBER. Adaptive Designs for Clinical Trials of Drugs and Biologics Guidance for Industry. Technical report, Food and Drug Administration. 2019."},{"key":"2190_CR29","unstructured":"Committee for Proprietary Medicinal Products. Reflection Paper on Methodological Issues in Confirmatory Clinical Trials Planned with an Adaptive Design. Technical report, European Medicines Agency. 2007."}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-024-02190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-024-02190-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-024-02190-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T10:04:57Z","timestamp":1724061897000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-024-02190-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2190"],"URL":"https:\/\/doi.org\/10.1186\/s12874-024-02190-w","relation":{},"ISSN":["1471-2288"],"issn-type":[{"type":"electronic","value":"1471-2288"}],"subject":[],"published":{"date-parts":[[2024,3,28]]},"assertion":[{"value":"28 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}